# Expanded Access to Glecaprevir/ Pibrentasvir

> **NCT03123965** · — · APPROVED_FOR_MARKETING · sponsor: **AbbVie**

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** glecaprevir
- **DRUG:** pibrentasvir

## Key facts

- **NCT ID:** NCT03123965
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123965, "Expanded Access to Glecaprevir/ Pibrentasvir". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03123965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*